1) Contribute to the resolution of the genetic landscape of these disorders, with focus on common and rare variation, through GWAS and whole-exome/genome sequencing. We make emphasis on cross-disorder analysis, i.e. on defining shared vs specific genetic risk factors. Epigenetics, which mediates the interactions between environment and genome, and the transcriptome, are also being explored.

2) Perform functional studies in animal and cell models to study the relevance of candidate genes identified by us and to explore therapeutic targets.

3) Investigate the genetics of these disorders across the evolution of the human lineages, including modern and extinct Homo species, like the Neanderthals.

4) Translate our research to the clinical practice by participating in the development of diagnostic and pharmacogenetic tools that allow prognosis of severity/comorbidities/treatment response. All this will be possible thanks to the active involvement of our group into large international efforts like the Psychiatric Genomics Consortium (PGC), the participation in EU projects, and our tight collaboration with hospitals.

​

Some of our recent publications are listed below

​

​

​

​